Painful Boney Metastases

키워드

참고문헌 (103)

1. World cancer report 2008, "Boyle P", International Agency for Research on Cancer, ~ (2008)
2. Berruti A, "Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline", J Urol, 164, pp.1248~1253 (2000)
3. Meuser T, "Symptoms during cancer pain treatment following WHO-guidelines: a longitudinal follow-up study of symptom prevalence, severity and etiology", Pain, 93, pp.247~257 (2001)
4. van den Beuken-van Everdingen MH, "Prevalence of pain in patients with cancer: a systematic review of the past 40 years", Ann Oncol, 18, pp.1437~1449 (2007)
5. van den Beuken-van Everdingen MH, "High prevalence of pain in patients with cancer in a large population-based study in The Netherlands", Pain, 132, pp.312~320 (2007)
6. Laird BJ, "Characterization of cancer-induced bone pain: an exploratory study", Support Care Cancer, 19, pp.1393~1401 (2011)
7. Mercadante S, "Malignant bone pain: pathophysiology and treatment", Pain, 69, pp.1~18 (1997)
8. Delaney A, "Translational medicine: cancer pain mechanisms and management", Br J Anaesth, 101, pp.87~94 (2008)
9. Saftig P, "Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice", Proc Natl Acad Sci U S A, 95, pp.13453~13458 (1998)
10. Everts V, "The bone lining cell: its role in cleaning Howship's lacunae and initiating bone formation", J Bone Miner Res, 17, pp.77~90 (2002)
11. Sly WS, "Carbonic anhydrase II deficiency identified as the primary defect in the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification", Proc Natl Acad Sci U S A, 80, pp.2752~2756 (1983)
12. Josephsen K, "Targeted disruption of the Cl-", HCO3- exchanger Ae2 results in osteopetrosis in mice, 2009, pp.106, 1638~1641
13. Frattini A, "Defects in TCIRG1 subunit of the vacuolar proton pump are responsible for a subset of human autosomal recessive osteopetrosis", Nat Genet, 25, pp.343~346 (2000)
14. Karsdal MA, "Acidification of the osteoclastic resorption compartment provides insight into the coupling of bone formation to bone resorption", Am J Pathol, 166, pp.467~476 (2005)
15. Baron R, "Cell-mediated extracellular acidification and bone resorption: evidence for a low pH in resorbing lacunae and localization of a 100-kD lysosomal membrane protein at the osteoclast ruffled border", J Cell Biol, 101, pp.2210~2222 (1985)
16. Miyazaki T, "The role of c-Src kinase in the regulation of osteoclast function", Mod Rheumatol, 16, pp.68~74 (2006)
17. Bradt J, "Music interventions for improving psychological and physical outcomes in cancer patients", Cochrane Database Syst Rev, (8), pp.CD006911~ (2011)
18. Jane SW, "Effects of massage on pain, mood status, relaxation, and sleep in Taiwanese patients with metastatic bone pain: a randomized clinical trial", Pain, 152, pp.2432~2442 (2011)
19. Burton AW, "Cancer pain: progress since the WHO guidelines", Pain Pract, 1, pp.236~242 (2001)
20. Zech DF, "Validation of World Health Organization Guidelines for cancer pain relief: a 10-year prospective study", Pain, 63, pp.65~76 (1995)
21. Mercadante S, "Intravenous morphine for management of cancer pain", Lancet Oncol, 11, pp.484~489 (2010)
22. Vielhaber A, "Advances in cancer pain management", Hematol Oncol Clin North Am, 16, pp.527~541 (2002)
23. Urch C, "The pathophysiology of cancer-induced bone pain: current understanding", Palliat Med, 18, pp.267~274 (2004)
24. Eisenberg E, "Efficacy and safety of nonsteroidal antiinflammatory drugs for cancer pain: a meta-analysis", J Clin Oncol, 12, pp.2756~2765 (1994)
25. Levick S, "Naproxen sodium in treatment of bone pain due to metastatic cancer", Pain, 35, pp.253~258 (1988)
26. Stambaugh JE Jr, "The combination of ibuprofen and oxycodone", acetaminophen in the management of chronic cancer pain, 1988, pp.44, 665~669
27. Sacchetti G, "Injectable ketoprofen vs. acetylsalicylic acid for the relief of severe cancer pain: a double-blind, crossover trial", Drug Intell Clin Pharm, 18, pp.403~406 (1984)
28. McNicol E, "NSAIDS or paracetamol, alone or combined with opioids, for cancer pain", Cochrane Database Syst Rev, (1), pp.CD005180~ (2005)
29. Sheng H, "Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2", J Clin Invest, 99, pp.2254~2259 (1997)
30. Sabino MA, "Simultaneous reduction in cancer pain, bone destruction, and tumor growth by selective inhibition of cyclooxygenase-2", Cancer Res, 62, pp.7343~7349 (2002)
31. Isono M, "Microsomal prostaglandin E synthase-1 enhances bone cancer growth and bone cancer-related pain behaviors in mice", Life Sci, 88, pp.693~700 (2011)
32. Bruera E, "Action of oral methylprednisolone in terminal cancer patients: a prospective randomized double-blind study", Cancer Treat Rep, 69, pp.751~754 (1985)
33. Cain DM, "Functional interactions between tumor and peripheral nerve: changes in excitability and morphology of primary afferent fibers in a murine model of cancer pain", J Neurosci, 21, pp.9367~9376 (2001)
34. Peters CM, "Tumor-induced injury of primary afferent sensory nerve fibers in bone cancer pain", Exp Neurol, 193, pp.85~100 (2005)
35. Halvorson KG, "Similarities and differences in tumor growth, skeletal remodeling and pain in an osteolytic and osteoblastic model of bone cancer", Clin J Pain, 22, pp.587~600 (2006)
36. Jimenez-Andrade JM, "Cancer pain: from the development of mouse models to human clinical trials. In: Translational pain research: from mouse to man", pp.1~22 (2010), CRC Press
37. Donovan-Rodriguez T, "Gabapentin normalizes spinal neuronal responses that correlate with behavior in a rat model of cancer-induced bone pain", Anesthesiology, 102, pp.132~140 (2005)
38. Caraceni A, "Gabapentin for neuropathic cancer pain: a randomized controlled trial from the Gabapentin Cancer Pain Study Group", J Clin Oncol, 22, pp.2909~2917 (2004)
39. Caraceni A, "Gabapentin for breakthrough pain due to bone metastases", Palliat Med, 22, pp.392~393 (2008)
40. Kato A, "Oxycodone-induced analgesic effects in a bone cancer pain model in mice", Oncology, 74(Suppl 1), pp.55~60 (2008)
41. Bailey F, "Oral opioid drugs. In: Cancer-related breakthrough pain", pp.43~55 (2006), Oxford University Press
42. Portenoy RK, "Breakthrough pain: characteristics and impact in patients with cancer pain", Pain, 81, pp.129~134 (1999)
43. Costa L, "Effect of bisphosphonates on pain and quality of life in patients with bone metastases", Nat Clin Pract Oncol, 6, pp.163~174 (2009)
44. Mönkkönen H, "A new endogenous ATP analog (ApppI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen-containing bisphosphonates", Br J Pharmacol, 147, pp.437~445 (2006)
45. Berenson JR, "American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma", J Clin Oncol, 20, pp.3719~3736 (2002)
46. Pistevou-Gombaki K, "Palliative treatment of painful bone metastases from non-Hodgkin lymphoma with disodium pamidronate", J Exp Clin Cancer Res, 21, pp.429~432 (2002)
47. Santini D, "Zoledronic acid in the management of metastatic bone disease", Expert Opin Biol Ther, 6, pp.1333~1348 (2006)
48. Amir E, "Radiological changes following second-line zoledronic acid treatment in breast cancer patients with bone metastases", Clin Exp Metastasis, 26, pp.479~484 (2009)
49. Hiraga T, "Zoledronic acid inhibits visceral metastases in the 4T1", luc mouse breast cancer model, 2004, pp.10, 4559~4567
50. Furlow B, "Zoledronic acid palliation in bone-metastatic breast cancer", Lancet Oncol, 7, pp.894~ (2006)
51. Fulfaro F, "The use of zoledronic acid in patients with bone metastases from prostate carcinoma: effect on analgesic response and bone metabolism biomarkers", J Chemother, 17, pp.555~559 (2005)
52. Rachner TD, "Zoledronic acid induces apoptosis and changes the TRAIL", OPG ratio in breast cancer cells, 2010, pp.287, 109~116
53. Woodward JK, "Combined effects of zoledronic acid and doxorubicin on breast cancer cell invasion in vitro", Anticancer Drugs, 16, pp.845~854 (2005)
54. Santini D, "Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients", Clin Cancer Res, 13, pp.4482~4486 (2007)
55. Vincenzi B, "Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients", J Interferon Cytokine Res, 25, pp.144~151 (2005)
56. Tong D, "The palliation of symptomatic osseous metastases: final results of the study by the Radiation Therapy Oncology Group", Cancer, 50, pp.893~899 (1982)
57. Arcangeli G, "The responsiveness of bone metastases to radiotherapy: the effect of site, histology and radiation dose on pain relief", Radiother Oncol, 14, pp.95~101 (1989)
58. Dennis K, "Palliative radiotherapy for bone metastases in the last 3 months of life: worthwhile or futile?", Clin Oncol (R Coll Radiol), 23, pp.709~715 (2011)
59. Poulter CA, "A report of RTOG 8206: a phase III study of whether the addition of single dose hemibody irradiation to standard fractionated local field irradiation is more effective than local field irradiation alone in the treatment of symptomatic osseous metastases", Int J Radiat Oncol Biol Phys, 23, pp.207~214 (1992)
60. Jeremic B, "Single fraction external beam radiation therapy in the treatment of localized metastatic bone pain. A review", J Pain Symptom Manage, 22, pp.1048~1058 (2001)
61. Wu JS, "Meta-analysis of dose-fractionation radiotherapy trials for the palliation of painful bone metastases", Int J Radiat Oncol Biol Phys, 55, pp.594~605 (2003)
62. Sze WM, "Palliation of metastatic bone pain: single fraction versus multifraction radiotherapy--a systematic review of randomised trials", Clin Oncol (R Coll Radiol), 15, pp.345~352 (2003)
63. Chow E, "Palliative radiotherapy trials for bone metastases: a systematic review", J Clin Oncol, 25, pp.1423~1436 (2007)
64. Rades D, "Treatment of painful bone metastases", Nat Rev Clin Oncol, 7, pp.220~229 (2010)
65. Nomiya T, "Time course of pain relief in patients treated with radiotherapy for cancer pain: a prospective study", Clin J Pain, 26, pp.38~42 (2010)
66. Huisman M, "Effectiveness of reirradiation for painful bone metastases: a systematic review and meta-analysis", Int J Radiat Oncol Biol Phys, 84, pp.8~14 (2012)
67. Smith H, "Radiopharmaceuticals for palliation of painful osseous metastases", Am J Hosp Palliat Care, 21, pp.303~313 (2004)
68. Roqué I Figuls M, "Radioisotopes for metastatic bone pain", Cochrane Database Syst Rev, (7), pp.CD003347~ (2011)
69. Paes FM, "Systemic metabolic radiopharmaceutical therapy in the treatment of metastatic bone pain", Semin Nucl Med, 40, pp.89~104 (2010)
70. Robinson RG, "Radionuclide therapy of intractable bone pain: emphasis on strontium-89", Semin Nucl Med, 22, pp.28~32 (1992)
71. Finlay IG, "Radioisotopes for the palliation of metastatic bone cancer: a systematic review", Lancet Oncol, 6, pp.392~400 (2005)
72. "Samarium-153 lexidronam for painful bone metastases", Med Lett Drugs Ther, 39, pp.83~84 (1997)
73. Alberts AS, "Dose response relationship and multiple dose efficacy and toxicity of samarium-153-EDTMP in metastatic cancer to bone", Radiother Oncol, 43, pp.175~179 (1997)
74. Sartor O, "Safety and efficacy of repeat administration of samarium Sm-153 lexidronam to patients with metastatic bone pain", Cancer, 109, pp.637~643 (2007)
75. Nazario J, "Thermal ablation of painful bone metastases", Tech Vasc Interv Radiol, 14, pp.150~159 (2011)
76. Callstrom MR, "Image-guided palliation of painful metastases using percutaneous ablation", Tech Vasc Interv Radiol, 10, pp.120~131 (2007)
77. Di Staso M, "A feasibility study of percutaneous radiofrequency ablation followed by radiotherapy in the management of painful osteolytic bone metastases", Eur Radiol, 21, pp.2004~2010 (2011)
78. Dupuy DE, "Radiofrequency ablation of spinal tumors: temperature distribution in the spinal canal", AJR Am J Roentgenol, 175, pp.1263~1266 (2000)
79. Tancioni F, "Percutaneous vertebral augmentation in metastatic disease: state of the art", J Support Oncol, 9, pp.4~10 (2011)
80. Peh WC, "Percutaneous vertebroplasty: indications, contraindications, and technique", Br J Radiol, 76, pp.69~75 (2003)
81. Lee B, "The efficacy of percutaneous vertebroplasty for vertebral metastases associated with solid malignancies", Eur J Cancer, 45, pp.1597~1602 (2009)
82. Saliou G, "Percutaneous vertebroplasty for pain management in malignant fractures of the spine with epidural involvement", Radiology, 254, pp.882~890 (2010)
83. Kassamali RH, "Pain management in spinal metastases: the role of percutaneous vertebral augmentation", Ann Oncol, 22, pp.782~786 (2011)
84. Qian Z, "Kyphoplasty for the treatment of malignant vertebral compression fractures caused by metastases", J Clin Neurosci, 18, pp.763~767 (2011)
85. Smith TJ, "Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival", J Clin Oncol, 20, pp.4040~4049 (2002)
86. Deer T, "Polyanalgesic consensus conference 2007: recommendations for the management of pain by intrathecal (intraspinal) drug delivery: report of an interdisciplinary expert panel", Neuromodulation, 10, pp.300~328 (2007)
87. Deer TR, "Comprehensive consensus based guidelines on intrathecal drug delivery systems in the treatment of pain caused by cancer pain", Pain Physician, 14, pp.E283~E312 (2011)
88. Papachristou DJ, "Bone metastases: molecular mechanisms and novel therapeutic interventions", Med Res Rev, 32, pp.611~636 (2012)
89. Kong YY, "Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand", Nature, 402, pp.304~309 (1999)
90. Hsu H, "Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand", Proc Natl Acad Sci U S A, 96, pp.3540~3545 (1999)
91. Body JJ, "A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases", Cancer, 97, pp.887~892 (2003)
92. Schwarz EM, "Clinical development of anti- RANKL therapy", Arthritis Res Ther, 9(Suppl 1), pp.S7~ (2007)
93. Kaan TK, "Systemic blockade of P2X3 and P2X2", 3 receptors attenuates bone cancer pain behaviour in rats, 2010, pp.133, 2549~2564
94. Chen J, "P2Y1 purinoceptor inhibition reduces extracellular signal-regulated protein kinase 1", 2 phosphorylation in spinal cord and dorsal root ganglia: implications for cancer-induced bone pain, 2012, pp.44, 367~372
95. Tomura H, "Proton-sensing and lysolipid-sensitive G-protein-coupled receptors: a novel type of multi-functional receptors", Cell Signal, 17, pp.1466~1476 (2005)
96. Huang CW, "Nociceptors of dorsal root ganglion express proton-sensing G-protein-coupled receptors", Mol Cell Neurosci, 36, pp.195~210 (2007)
97. Chen YJ, "Expression and function of proton-sensing G-protein-coupled receptors in inflammatory pain", Mol Pain, 5, pp.39~ (2009)
98. Pérez-Sayáns M, "V-ATPase inhibitors and implication in cancer treatment", Cancer Treat Rev, 35, pp.707~713 (2009)
99. Reeh PW, "Tissue acidosis in nociception and pain", Prog Brain Res, 113, pp.143~151 (1996)
100. Sin WC, "G protein-coupled receptors GPR4 and TDAG8 are oncogenic and overexpressed in human cancers", Oncogene, 23, pp.6299~6303 (2004)
101. Hang LH, "Activation of spinal TDAG8 and its downstream PKA signaling pathway contribute to bone cancer pain in rats", Eur J Neurosci, 36, pp.2107~2117 (2012)
102. Lozano-Ondoua AN, "Disease modification of breast cancer-induced bone remodeling by cannabinoid 2 receptor agonists", Bone Miner Res, 28, pp.92~107 (2013)
103. Hu S, "Lipoxins and aspirin-triggered lipoxin alleviate bone cancer pain in association with suppressing expression of spinal proinflammatory cytokines", J Neuroinflammation, 9, pp.278~ (2012)

관련 논문AI추천